Free Trial

89bio Q2 2023 Earnings Report

89bio logo
$7.91 -0.07 (-0.88%)
(As of 09:33 AM ET)

89bio Earnings Headlines

89bio Strengthens Leadership Retention with New RSUs
Analysts Set 89bio, Inc. (NASDAQ:ETNB) PT at $30.33
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
See More 89bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89bio and other key companies, straight to your email.

About 89bio

89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89bio Profile

More Earnings Resources from MarketBeat

Upcoming Earnings